Overview
- 26 inspections across 26 sites are on record.
- 94 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2026-05-15.
At a glance
Inspections
26
Sites
26
Observations
94
Career since
Jul 2021
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Genentech, Inc. | 15 May 2026 | Human Drugs | |
| AMPAC Fine Chemicals LLC | 10 Sep 2025 | Human Drugs | |
| Intersect ENT, Inc. | 7 Aug 2025 | Human Drugs | |
| Nova Pneuma, Inc. | 1 Aug 2025 | Human Drugs | |
| Najafi Pharma, Inc. | 9 Jul 2025 | Human Drugs | View 483 → |
Sites inspected
Genentech, Inc.South San Francisco, United States1 insp.
AMPAC Fine Chemicals LLCRancho Cordova, United States1 insp.
Intersect ENT, Inc.Menlo Park, United States1 insp.
Nova Pneuma, Inc.Fremont, United States1 insp.
Najafi Pharma, Inc.Alameda, United States1 insp.
Co-investigators
Investigators who share inspections with this person.
Matthew R Clabeaux4 shared
Anney Lin3 shared
Joey V Quitania2 shared
Tiara M Brown2 shared
Linda Thai2 shared
Jolanna A Norton2 shared
Jeffrey P Raimondi2 shared
Crystal Monroy1 shared
Andrew Le1 shared
Jennifer Crumb1 shared
Full investigator report
Get the verbatim findings behind Gunneet Kaur's 94 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site